Myocardial Infarction Treatment Market - Global Industry Analysis

Myocardial Infarction Treatment Market

Myocardial Infarction Treatment Market By Product Type (Antiplatelet Agents, Glycoprotein IIb/IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers, Vasodilators, Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin-Receptor Blockers, Analgesics, Thrombolytics); Distribution Channel (Hospitals, Hospital Pharmacies, Drug Stores And Online Drug Stores); And Region: Global Industry Perspective, Comprehensive Analysis And Forecast, 2020 – 2028

Published Date: 15-Jul-2021 Category: Pharmaceutical Report Format : PDF Pages: 155 Report Code: ZMR-1084 Status : Published

The global Myocardial Infarction Treatment market accounted for USD 1553 Million in 2020 and is expected to reach USD 2246.10 Million by 2028, growing at a CAGR of around 4.6% between 2021 and 2028.

Myocardial Infarction Treatment Market

Description

Market Overview     

The global Myocardial Infarction Treatment market accounted for USD 1553 Million in 2020 and is expected to reach USD 2246.10 Million by 2028, growing at a CAGR of around 4.6% between 2021 and 2028.

Growing cases of cardiovascular ailments and sedentary life patterns will impact the expansion of the myocardial infarct treatment market within the years ahead. Besides this, factors like obesity, diabetes, smoking habits, hypertension, low physical activity, and diabetes are anticipated to impact the expansion of the myocardial infarct treatment market within the near future. Escalating drug costs alongside growing expenditure on clinical trials are probably going to hamper the expansion of the myocardial infarct treatment market within the coming years.

Furthermore, rising costs of R& D programs alongside strict legislation governing the treatment can obstruct the business growth within the ensuing years. Nonetheless, mounting adoption of innovative treatment methods across developing nations will boost the industry revenue, thereby normalizing the impact of hindrances on the myocardial infarct treatment market, reports the myocardial infarct treatment market study.

COVID-19 Impact Analysis  

Besides, the COVID-19 outbreak, there's a drastic rise in the demand for healthcare facilities across the world. 2020 has been a dramatic rush of ICU visits and checkups so far, all because of a pandemic that has shaken the entire world. The Novel Coronavirus that caused the COVID-19 disease unleashed a disaster of extraordinary proportions. As healthcare spends for COVID-19 increases exponentially, companies that conduct research, develop potential vaccines, produce test kits, and manufacture or supply medical equipment are likely to benefit the most. The reason is clear - governments across the world will invest in not only damage control, but also in the prevention of any potential resurgence of the pandemic. This also means that companies other than those manufacturing PPE or infrastructure support that is not directly connected to COVID-19 would face disruptions in business.

Growth Factors

Globally, the increasing incidence of arteria coronaria disease and changes in lifestyle, an increasing number of smokers, increasing incidence of obesity, and lack of exercise are the prime growth drivers of the worldwide myocardial infarct Treatment market. Additionally, an increase in the adoption of myocardial infarct Treatment in emerging economies like China, India among others, will create new opportunities for the global myocardial infarct Treatment market. However, the upper cost of research and development, and limited R&D Activities are the key restraints for the global myocardial infarct Treatment market.

Report Scope:  

Report Attribute Details
Base Year 2020
Historic Years 2016 - 2020
Forecast Years 2021 - 2028
Segments Covered By Product Type, By Application, and By End Use
Forecast Units Value (USD Billion), and Volume (Units)
Quantitative Units Revenue in USD million/billion and CAGR from 2021 to 2028
Regions Covered North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World
Countries Covered U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others
Number of Companies Covered 10 companies with scope for including additional 15 companies upon request
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.
Customization Scope Avail customized purchase options to meet your exact research needs.

Segment Analysis Preview  

Based on product type the market is segmented into antiplatelet agents, glycoprotein IIb/IIIa inhibitors, antithrombotic agents, beta-adrenergic blockers, vasodilators, angiotensin-converting enzyme (ace) inhibitors, angiotensin-receptor blockers, analgesics, thrombolytics. Key distribution channels covered under this study include hospitals, hospital pharmacies, drug stores, and online drug stores. 

Based on distribution channels, hospitals and hospital pharmacies both have accounted for the major market share in 2018 due to the increased investments in healthcare infrastructure & the use of advanced technologies. However, online drug stores are expected to witness the fastest growth within the forecast period due to increasing demand from healthcare participants in surgical care such as; healthcare professionals, patients, and insurers. Additionally, increasing demand for patient satisfaction, cost-effective procedures, and efficient practices by healthcare professionals also are expected to spice up the expansion of this market within the forecast period.

Regional Analysis Preview

Regionally, North America has been leading the worldwide myocardial infarct treatment market and is anticipated to continue on the dominant position within the years to return. The rise in the geriatric population base and growing cases of heart ailments is that the main factor behind the dominance of the North American myocardial infarct treatment market. The high number of market players being headquartered in North America is another significant factor that's supporting this regional myocardial infarct treatment market.

Key Market Players & Competitive Landscape

The major players that are comprised in  Myocardial Infarction Treatment market are Bayer, Novartis, Daiichi Sankyo Company Limited, Boehringer Ingelheim GmbH, Sandoz, Astrazeneca, Janssen Biotech, Inc., Merck & Co. Inc., Sanofi, Pfizer Inc. among others.

The global  Myocardial Infarction Treatment Market is segmented as follows:

By Product Type

  • Antiplatelet agents
  • Glycoprotein IIb/IIIa inhibitors
  • Antithrombotic agents
  • Beta-adrenergic blockers
  • Vasodilators
  • Angiotensin-Converting Enzyme (ACE) inhibitors
  • Angiotensin-Receptor blockers
  • Analgesics
  • Thrombolytics

By Distribution Channel

  • Hospitals
  • Hospital Pharmacies
  • Drug Stores
  • Online Drug Stores

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

Methodology

Free Analysis

Myocardial Infarction (MI) also called heart attack is caused when the oxygen-rich blood supply to heart muscle is hindered due to blockage of the coronary artery. As oxygen supply is blocked, the heart muscles begin to die. The blockage is the result of plaque formation on the inside walls of arteries. Plaque formation process is called atherosclerosis. Plaque is built up over many years. Plaque formed may rupture inside the artery leading to blood clot formation inside arteries, thus blocking the blood flow and leading to heart attack. As per CDC’s 2016 report, the Heart attack was the leading cause of death for both men and women and accounted for nearly 1 of every 4 deaths. As per WHO, there are 32.4 million myocardial infarctions and strokes worldwide every year. The treatment of myocardial infarction has become of prime importance owing to increase in a number of global myocardial infarction patients. Different types of treatments are available to treat myocardial infarction patients depending upon therapy used to treat the patient and severity of the disease.

Growing incidences of cardiovascular diseases and sedentary lifestyle are expected to be the major drivers for the global myocardial infarction treatment market. Also, increased incidences of obesity, diabetes, hypertension and rise in a number of smokers, reduced physical activities are expected to trigger the growth of global myocardial infarction treatment industry in the coming years. However, the high price of drug research and development and stringent regulatory policies coupled with high cost of clinical trials may pose the challenge to myocardial infarction treatment market. Nevertheless, increase in acceptance of newer treatment technologies by emerging nations and technology breakthroughs are expected to act an opportunity for myocardial infarction treatment market in near future.

Based on product type, myocardial infarction treatment market has been segmented into Antiplatelet agents, Glycoprotein IIb/IIIa inhibitors, Antithrombotic agents, Beta-adrenergic blockers, Vasodilators, Angiotensin-Converting Enzyme (ACE) inhibitors, Angiotensin-Receptor blockers, Analgesics, Thrombolytics. Analgesics and antiplatelet agent segments are expected to grow at the fastest rate during the forecast period. The myocardial infarction treatment market is segmented based on distribution channel into Hospitals, Hospital Pharmacies, Drug Stores and Online Drug Stores. Based on geography, the myocardial infarction treatment market is segmented into North America, Europe, Asia-Pacific, Latin America and the Middle East and Africa.  In terms of revenue, analgesics and antiplatelet agent are foreseen to dominate the market.

North America is expected to remain the dominant region over the forecast period. Increased incidences of cardiovascular diseases and rising aging population expected to boost the market in this region. Expiration of blockbuster drugs in the European market will impact global market share of myocardial infarction treatment market. Also, Asia Pacific market is projected to grow during the forecast period due to an accelerated increase in aging population and increasing awareness. Latin America and Middle East & Africa regions are also expected to experience noticeable growth in the years to come owing to the high incidence rate of cardiovascular diseases.

Some of the key players in myocardial infarction treatment market include Bayer, Novartis, Daiichi Sankyo Company Limited, Boehringer Ingelheim GmbH, Sandoz, Astrazeneca, Janssen Biotech, Inc., Merck & Co. Inc., Sanofi, Pfizer Inc. among others.

FrequentlyAsked Questions

The global  Myocardial Infarction Treatment Market was valued at USD 1553 Million in 2020.

The global  Myocardial Infarction Treatment Market is expected to reach USD 2246 Million by 2028, growing at a CAGR of 4.6% between 2021 to 2028.

Factors such as the increasing incidence of cancer, growth in the elderly population, healthcare infrastructure improvements, and the increasing prevalence of chronic diseases are the major factors driving the market growth.

North America in 2020 ruled the  Myocardial Infarction Treatment market and was believed to be the highest income-generating area all over the globe.  

The major players that are comprised in  Myocardial Infarction Treatment market are Bayer, Novartis, Daiichi Sankyo Company Limited, Boehringer Ingelheim GmbH, Sandoz, Astrazeneca, Janssen Biotech, Inc., Merck & Co. Inc., Sanofi, Pfizer Inc. among others.

Choose License Type

  • zion payment modes

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008

Contact #

US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • payment methods

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed